Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28815055 | 0.89 | LMNA (0.62) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL746794 | 0.87 | LMNA (0.64) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL10911687 | 0.85 | LMNA (0.52) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL31319408 | 0.85 | LMNA (0.52) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL3186240 | 0.80 | LMNA (0.53) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL3717986 | 0.79 | GAA (0.56) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL31369140 | 0.79 | GAA (0.56) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL11459852 | 0.77 | RORC (0.51) | LMNAGAACNR2SMN1; SMN2MAPK14 | |
| SCHEMBL221518 | 0.77 | LMNA (0.62) | LMNAGAACNR2KCNK3KCNK9 | |
| SCHEMBL30449216 | 0.77 | LMNA (0.62) | LMNAGAACNR2KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | MIF, FOXM1, HMGB3 | LMNA 1791/4885GAA 4137/4885CNR2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.